Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 9/20 | 0.37 |
| ▸ | CTSB | P07858 | 6/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19764741 | 0.85 | MEN1 (0.40) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL894621 | 0.84 | MEN1 (0.39) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL17896127 | 0.83 | MEN1 (0.39) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL895661 | 0.83 | KMT2A (0.39) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL8727726 | 0.80 | MEN1 (0.49) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL17902798 | 0.79 | SYK (0.44) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL10266056 | 0.79 | MEN1 (0.40) | CTSSMEN1KMT2AALDH1A1MBOAT4 | |
| SCHEMBL895100 | 0.78 | MEN1 (0.37) | MEN1KMT2APTPN2PTPN1PTPRB | |
| SCHEMBL2300846 | 0.78 | MEN1 (0.47) | CTSSMEN1KMT2APTPN2PTPN1 | |
| SCHEMBL2297940 | 0.77 | MEN1 (0.46) | CTSSMEN1KMT2APTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240777-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-07-24 | — | — | EP | disclosed |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2019-06-25 | — | — | US | disclosed |
| US-20180009830-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2018-01-11 | — | — | US | disclosed |
| EP-3240777-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS S.A. (PL) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016108707-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016108707-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009830-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | CTSS 300/4885MEN1 3259/4885KMT2A 843/4885 |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, PRMT1 | CTSS 300/4885MEN1 3259/4885KMT2A 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.